Figure 5.

B and T Cell Interactions Shape Clinical Responses to Immune Checkpoint Blockade Independent of Tumor Mutation Burden

Immunoglobulin rearrangements highly correlated with TCR rearrangements in tumors of responders (Spearman rho = 0.68; p = 1e−06), delineating a group of patients that derived benefit from immune checkpoint blockade (shown as blue circles and triangles and clustered in the right upper corner of the plot). This correlation between pre-existing B and T cell rearrangements with each other and with response to therapy was not affected by TMB. Circles indicate treatment with ipilimumab and nivolumab, although triangles denote treatment with nivolumab. Responders are shown in blue and non-responders in magenta. The size of each point (solid circle or triangle) is proportional to the TMB of the corresponding baseline tumor.